Pfizer has been leaning on recently acquired products to offset a looming patent cliff.

Pfizer (NYSE:PFE) is preparing multiple presentations for the upcoming ASCO conference that spotlight new data across its ...

Q1 earnings May 4: analyst EPS/revenue estimates, 2026 guidance focus, oncology & obesity pipeline catalysts, and cost cuts.

Pfizer's vaccine business cooled off, and it is on its back foot in the GLP-1 race, but don't count the drug giant out.

Pfizer continues delivering consistent earnings beats, driven by cost-cutting initiatives and improving margins. Learn more ...

Pfizer is facing a patent cliff and has a high payout ratio, but it is taking steps to get back on track. That kind of price decline doesn't happen by accident, which means you need to carefully ...

(PFE) is running a Phase 2 trial of ritlecitinib in adults with moderate to severe hidradenitis suppurativa, a chronic skin disease that causes painful lumps. The study, officially titled “A Phase 2, ...

Track Pfizer share price today on NSE/BSE with real-time updates. Check stock performance, fundamentals, market cap, ...

During Pfizer's right-sizing push after the COVID-19 pandemic, the company's multibillion-dollar cost-cutting campaign has ...